No state-backed indemnity for pharmacy is ‘unfair’ and ‘extraordinary’

Pharmacies not being granted state indemnity insurance for COVID-19 vaccinations from November is “unfair” and “extraordinary”, sector bodies have said.

covid%20vaccine.jpg
AIMp and PSNC are watching discussions between government and sector insurance providers

Speaking at a webinar for community pharmacies and GP practices last week (July 15), NHS England and NHS Improvement (NHSE&I) director of primary care vaccination Caroline Temmink said that community pharmacies will have to pay for indemnity cover in the third phase of the COVID-19 vaccination programme, while GPs will still be covered by a state-backed scheme.

Following this announcement, the Royal Pharmaceutical Society (RPS) wrote to vaccines minister Nadhim Zahawi, calling for the previous state-backed scheme – the Clinical Negligence Scheme for Coronavirus (CNSC) – to continue.

RPS English board chair Thorrun Govind said she was “surprised and concerned” that pharmacies would no longer benefit for state-backed indemnity for the booster vaccination programme.

“Expecting community pharmacists to now start paying for their own indemnity insurance is an extraordinary position,” she said in the email to Mr Zawahi, sent July 22.

“This creates an unnecessary and avoidable barrier to boosting the number of vaccinators and is inequitable with other health professions.”

AIMp and PSNC keeping an eye on talks

Association of Independent Multiple pharmacies (AIMp) CEO Leyla Hannbeck told C+D it would be “unfair if pharmacy is being asked to operate under a different set of rules from the rest of the NHS” for providing the same service.

“We are keeping a close eye on the current discussions between the government and indemnity insurance providers and we are asking that pharmacies are not penalised for wanting to continue their support in delivering care to patients and to participate in the vaccination programme,” Dr Hannbeck said.

The Pharmaceutical Services Negotiating Committee (PSNC) told C+D it too has pressed for state indemnity for pharmacists to continue into phase 3 of the COVID-19 vaccination programme.

“However, the Department of Health and Social Care (DH) is proposing shared indemnity cover – part private, insurance market, part state indemnity- followed by only private, insurance market cover,” PSNC director of operations and support Gordon Hockey explained.

“If the DH proposals are adopted, it will be important that contractors have access to relevant private, insurance market cover, to be able to offer the booster service to patients,” he advised.

“We will keep an eye on the discussions between government and pharmacy insurers to ensure that contractors are supported on this issue.”

Sign in or register for free

Latest from News

Sebco coal tar scalp ointment appointed by DHSC to support current shortages

 • comment1

Due to shortages in coal tar scalp ointment, the DHSC has asked the manufacturer of an equivalent product - Sebco - to provide increased stock levels to support patients during this time.

Pharmacies to boost naloxone stock amid ‘sudden’ overdose spike

 
• By 
 • comment0

Pharmacies in Scotland have been asked to ensure they have the “appropriate stock” of naloxone – a medicine used to reverse the effects of an opiate overdose – following an “increase in sudden collapse” due to overdoses.

Cuts and commissioning: What does NHSE’s axing mean for ICBs?

 
• By 
 • comment5

As the dust settles on the announcement that NHS England (NHSE) is set for the scrapheap, questions on what a 50% headcount cut means for local commissioners remain…

More from Business

breaking news

IN FULL: Boots’ parent company sold in $24bn private equity deal

 
• By 
 • comment

Walgreens Boots Alliance (WBA) has “entered into a definitive agreement to be acquired” by private equity firm Sycamore Partners.

Jhoots accounts: Shareholder funds tumble while debts soar

 
• By 
 • comment

Jhoots Chemist’s accounts for 2024 have revealed an almost £2 million year-on-year dip in shareholder funds – as debts to creditors increase more than £2m.